Business Context and Reporting Period
This Form 8-K Current Report was filed by TherapeuticsMD, Inc. on March 26, 2020. The filing primarily addresses the impact of the global COVID-19 pandemic on the Company's operations and financial outlook. It includes a business update regarding the suspension of 2020 financial guidance and the implementation of a comprehensive contingency plan.
Key Financial Metrics and Liquidity
This filing is a current report and does not contain audited financial statements, revenue figures, profit margins, or specific cash flow data for the period. However, it details significant planned financial actions to preserve liquidity:
- Marketing Deferral: Approximately $10 million in consumer and healthcare practitioner marketing spending for ANNOVERA and IMVEXXY will be deferred.
- Expense Reductions: Approximately $20 million in other planned expenses for the year will be cut.
- Cost Containment: The Company plans to negotiate lower fees with non-critical vendors, implement a hiring freeze, delay non-critical IT projects, and eliminate travel and entertainment expenses.
- Liquidity Risks: The Company notes it may require increased working capital if billing and collection cycles are extended due to the pandemic.
Material Changes and Operational Impact
The primary material change is the suspension of previously issued 2020 financial guidance due to the inability to predict the impact of COVID-19. Operational changes include:
- Sales Force: Transitioned largely to digital engagement tools and virtual detailing due to travel restrictions.
- Supply Chain: While wholesale and retail distribution currently remain uninterrupted, the Company warns of potential disruptions in obtaining supplies or manufacturing components.
- Executive Action: Mitchell Krassan, Chief Strategy & Performance Officer, terminated his 10b5-1 trading plan on March 23, 2020. Approximately 489,658 options were not sold under this plan.
Guidance, Outlook, and Risks
Guidance: The Company has explicitly suspended its 2020 financial guidance. Management states it is unable to predict the impact of the pandemic on financial results.
Risks and Contingencies:
- Pandemic Impact: The outbreak may materially adversely affect financial condition and results of operations for fiscal year 2020 and beyond.
- Regulatory and Product Risks: Risks include FDA approval uncertainties for BIJUVA, potential adverse side effects, and Paragraph IV notice letters regarding IMVEXXY and BIJUVA.
- Financing: Risks regarding the ability to comply with covenants under its term loan facility and obtain additional financing.
- Market Volatility: The trading price of common stock is noted as volatile.
Investor Verification Checklist
- Verify the specific details of the suspended 2020 financial guidance in prior filings to understand the baseline expectations.
- Monitor the Company's cash burn rate and working capital requirements given the $30 million in planned cost cuts and potential billing delays.
- Review the status of the term loan facility and any conditions required to draw additional tranches.
- Track the effectiveness of the digital sales strategy compared to historical in-person detailing performance.
- Watch for updates on FDA approvals for BIJUVA and the resolution of Paragraph IV notice letters for IMVEXXY and BIJUVA.